Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients.
<h4>Background</h4>Pulmonary hypertension (PH) is characterized by elevated pulmonary artery pressure but classified into subgroups based on disease etiology. It is established that systemic bioenergetic dysfunction contributes to the pathogenesis of pulmonary arterial hypertension class...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0220490 |
| _version_ | 1819037098428071936 |
|---|---|
| author | Quyen L Nguyen Yinna Wang Nicole Helbling Marc A Simon Sruti Shiva |
| author_facet | Quyen L Nguyen Yinna Wang Nicole Helbling Marc A Simon Sruti Shiva |
| author_sort | Quyen L Nguyen |
| collection | DOAJ |
| description | <h4>Background</h4>Pulmonary hypertension (PH) is characterized by elevated pulmonary artery pressure but classified into subgroups based on disease etiology. It is established that systemic bioenergetic dysfunction contributes to the pathogenesis of pulmonary arterial hypertension classified as World Health Organization (WHO) Group 1. Consistent with this, we previously showed that platelets from Group 1 PH patients demonstrate increased glycolysis and enhanced maximal capacity for oxidative phosphorylation, which is due to increased fatty acid oxidation (FAO). However, it remains unclear whether identical mitochondrial alterations contribute to the pathology of other PH subgroups. The most prevalent subgroup of PH is WHO Group 2, which encompasses pulmonary venous hypertension secondary to left heart disease. Here, we hypothesized that platelets from Group 2 subjects show bioenergetic alteration compared to controls, and that these changes were similar to Group 1 PH patients.<h4>Method and results</h4>We isolated platelets from subjects with Group 2 PH and controls (n = 20) and measured platelet bioenergetics as well as hemodynamic parameters. We demonstrate that Group 2 PH platelets do not show a change in glycolytic rate but do demonstrate enhanced maximal capacity of respiration due at least partially to increased FAO. Moreover, this enhanced maximal capacity correlates negatively with right ventricular stroke work index and is not changed by administration of inhaled nitrite, a modulator of pulmonary hemodynamics.<h4>Conclusions</h4>These data demonstrate that Group 2 PH subjects have altered bioenergetic function though this alteration is not identical to that of Group 1 PH. The implications of this alteration for disease pathogenesis will be discussed. |
| first_indexed | 2024-12-21T08:16:01Z |
| format | Article |
| id | doaj.art-cca569a02db644909dc2c0f25a5b8b0d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T08:16:01Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-cca569a02db644909dc2c0f25a5b8b0d2022-12-21T19:10:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01147e022049010.1371/journal.pone.0220490Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients.Quyen L NguyenYinna WangNicole HelblingMarc A SimonSruti Shiva<h4>Background</h4>Pulmonary hypertension (PH) is characterized by elevated pulmonary artery pressure but classified into subgroups based on disease etiology. It is established that systemic bioenergetic dysfunction contributes to the pathogenesis of pulmonary arterial hypertension classified as World Health Organization (WHO) Group 1. Consistent with this, we previously showed that platelets from Group 1 PH patients demonstrate increased glycolysis and enhanced maximal capacity for oxidative phosphorylation, which is due to increased fatty acid oxidation (FAO). However, it remains unclear whether identical mitochondrial alterations contribute to the pathology of other PH subgroups. The most prevalent subgroup of PH is WHO Group 2, which encompasses pulmonary venous hypertension secondary to left heart disease. Here, we hypothesized that platelets from Group 2 subjects show bioenergetic alteration compared to controls, and that these changes were similar to Group 1 PH patients.<h4>Method and results</h4>We isolated platelets from subjects with Group 2 PH and controls (n = 20) and measured platelet bioenergetics as well as hemodynamic parameters. We demonstrate that Group 2 PH platelets do not show a change in glycolytic rate but do demonstrate enhanced maximal capacity of respiration due at least partially to increased FAO. Moreover, this enhanced maximal capacity correlates negatively with right ventricular stroke work index and is not changed by administration of inhaled nitrite, a modulator of pulmonary hemodynamics.<h4>Conclusions</h4>These data demonstrate that Group 2 PH subjects have altered bioenergetic function though this alteration is not identical to that of Group 1 PH. The implications of this alteration for disease pathogenesis will be discussed.https://doi.org/10.1371/journal.pone.0220490 |
| spellingShingle | Quyen L Nguyen Yinna Wang Nicole Helbling Marc A Simon Sruti Shiva Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients. PLoS ONE |
| title | Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients. |
| title_full | Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients. |
| title_fullStr | Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients. |
| title_full_unstemmed | Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients. |
| title_short | Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients. |
| title_sort | alterations in platelet bioenergetics in group 2 ph hfpef patients |
| url | https://doi.org/10.1371/journal.pone.0220490 |
| work_keys_str_mv | AT quyenlnguyen alterationsinplateletbioenergeticsingroup2phhfpefpatients AT yinnawang alterationsinplateletbioenergeticsingroup2phhfpefpatients AT nicolehelbling alterationsinplateletbioenergeticsingroup2phhfpefpatients AT marcasimon alterationsinplateletbioenergeticsingroup2phhfpefpatients AT srutishiva alterationsinplateletbioenergeticsingroup2phhfpefpatients |